



Product Specification Sheet

EpiSep Anti-Urothelial (P1B5) & (LBS8)[®] Magnetic Particles

FOR RESEARCH USE ONLY: This product is not for diagnostic or therapeutic use.

Doc.# ML081006-11

CATALOG #: R2127-1

DESCRIPTION: EpiSep Anti-Urothelial (P1B5) & (LBS8)[®] Magnetic Particles are submicron uniform diameter, paramagnetic beads coated with mouse monoclonal P1B5 antibody and mouse monoclonal LBS8 antibody. The P1B5 antibody recognizes the alpha 3 subunit of VLA-3 (ECM1 - extracellular matrix receptor I, URO-1). The antibody detects 3 components of the alpha 3 subunit glycoprotein complex (MW 30kDa, 120kDa and 140kDa). VLA proteins are part of the integrin family of cell adhesion molecules. The LBS8 antibody recognizes only human urothelium. Urothelium consist of about 3-5 cell layers with a thick layer of protective glycoprotein plaques at its luminal surface.

**FOR RESEARCH
USE ONLY:**

This product is not for diagnostic or therapeutic use.

SUPPLIED AS: 1.0 mL of suspended magnetic particles in 0.020M Phosphate Buffer pH 7.4, 0.150M NaCl, 1.0% BSA, 0.1% Sodium Azide. Approximately 1mg/mL.

STABILITY: Recommended storage upon receipt is 4-8°C. **DO NOT FREEZE.** Stable when stored at 4-8°C. Can be stored for up to 12 months at 4-8°C. **DO NOT STORE AT ROOM TEMP.**

**APPLICATIONS
AND SUGGESTED
USE:**

Enrichment of urothelial cells for use with FISH, Immunocytochemistry, Flow Cytometry and PCR.

Re-suspend particles prior to each use by inversion several times. Generally, 25 μ L to 100 μ L of particles will be sufficient to capture cells in most specimens.

RELATED

PRODUCTS: EpiSep Alcohol Fixative™ (Cat#R2114-1)
EpiSep Hybridization Slide™ (Cat#A3104-10)
NeoMag Slide Dock for Hybridization Slide™ (Cat#A1103-1)
Magnetic Tube Dock, 50mL™ (Cat#A4101-1)

APPLICATION

SHEETS: EpiSep Preparation and Isolation of Urothelial Cells from Preserved Urine
for use with FISH. (Ref. Doc#ML080612-1)

MATERIAL

SAFETY DATA: When handling this material Standard Laboratory Practices should be followed. This material's chemical, physical and toxicological properties have not been thoroughly investigated. Contains Sodium Azide as a preservative. Although, the quantity of sodium azide (0.1%) is very small, measures should be taken to avoid skin and eye contact, inhalation and ingestion. Sodium Azide (NaN₃) may react with lead and copper plumbing to form potentially explosive metal oxides. Upon disposal, flush with a large volume of water to prevent Azide build-up.

REFERENCES:

1. Trejdosiewicz, L.K. 1985. Monoclonal antibodies to human urothelial cell lines and hybrids: production and characterization. *J Urol.* 133: 533-538.
2. Lorusso, V., Crucitta, E., Silvestris, N., Rosati, G., Manzione, L., De Lena, M., Palmeri, S., Gebbia, V., Mancarella, S., Sobrero, A., Pezzella, G., Comella, P., Mangiameli, A. and Muci, D. 2005. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the Urothelium. *Oncol. Rep.* 13: 283-287.
3. von der Maase, H. 2005. Pemetrexed in transitional cell carcinoma of the Urothelium. *Oncology* 18: 48-50.
4. Wein, A.J. 2005. Role of the Urothelium in bladder function. *J. Urol.* 173: 2199-2200.
5. Woodroffe, P.J., King, J.R., Varley, C.L. and Southgate, J. 2005. Modelling cell signalling and differentiation in the Urothelium. *Bull. Math Biol.* 67: 369-389.
6. Bellmunt, J., Albiol, S., de Olano, A.R., Pujadas, J. and Maroto, P. 2006. Gemcitabine in the treatment of advanced transitional cell carcinoma of the Urothelium. *Ann. Oncol.* 17 Suppl 5: v113-v117.

REFERENCES CONTINUED:

7. Khattab, M.M. and Al-Hrasen, M.N. 2006. Contractile activity of ATP and diadenosine tetraphosphate on urinary bladder in the rats: role of superoxide anion and Urothelium. *Auton. Autacoid Pharmacol.* 26: 149-156.
8. Lazzeri, M. 2006. The physiological function of the Urothelium—more than a simple barrier. *Urol. Int.* 76: 289-295.
9. Yoshida, M., Inadome, A., Maeda, Y., Satoji, Y., Masunaga, K., Sugiyama, Y. and Murakami, S. 2006. Non-neuronal cholinergic system in human bladder Urothelium. *Urology* 67: 425-430.
10. Tsuji, T., et al. 1991. Identification of human galactoprotein b3, an oncogenic transformation-induced membrane glycoprotein, as VLA-3 α subunit: the primary structure of human Integrin α 3. *J. Biochem.* 109: 659-665.
11. Hynes, R.O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. *Cell* 69: 11-25.
12. Clark, E.A., et al. 1995. Integrins and signal transduction pathways: the road taken. *Science* 268: 233-239.
13. Miyamoto, S., et al. 1995. Synergistic roles for receptor occupancy and aggregation in Integrin transmembrane function. *Science* 267: 883-885.
14. Sheppard, D. 1996. Epithelial Integrins. *BioEssays* 18: 655-660.
15. Juliano, R. 1996. Cooperation between soluble factors and Integrin-mediated cell anchorage in the control of cell growth and differentiation. *BioEssays* 18: 911-917.
16. de Melker, A.A., et al. 1997. The A and B variants of the α 3 Integrin subunit: tissue distribution and functional characterization. *Lab. Invest.* 76: 547-563.
17. Hirotsaki, T., et al. 2000. Structural requirement of carboxyl-terminal globular domains of Laminin α 3 chain for promotion of rapid cell adhesion and migration by Laminin 5. *J. Biol. Chem.* 275: 22495-22502.
18. Takada Y, Wayner EA, Carter WG, Hemler ME. Extracellular matrix receptors, ECMRII and ECMRI, for collagen and fibronectin correspond to VLA-2 and VLA-3 in the VLA family of heterodimers. *J Cell Biochem.* 1988 Aug;37(4):385–393.
19. EA Wayner, WG Carter, RS Piotrowicz, and TJ Kunicki
The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa. *J. Cell Biol.*, Nov 1988; 107: 1881 - 1891.